Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGvMED Study: Magnet System vs Semaglutide in Obesity and Type 2 Diabetes
NCT07317115Recruiting
- Sponsor
- GT Metabolic Solutions
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised trial in obesity and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by GT Metabolic Solutions. Primary endpoint: Hemoglobin A1c at 360 days. Started Mar 2026; status: recruiting.
02
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07317115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07317115.